Suppr超能文献

土拉弗朗西斯菌活疫苗株的一种确定的O抗原多糖突变体毒性减弱,同时保留了其保护能力。

A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.

作者信息

Sebastian Shite, Dillon Simon T, Lynch Jillian G, Blalock LeeAnn T, Balon Emmy, Lee Kristin T, Comstock Laurie E, Conlan J Wayne, Rubin Eric J, Tzianabos Arthur O, Kasper Dennis L

机构信息

Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Infect Immun. 2007 May;75(5):2591-602. doi: 10.1128/IAI.01789-06. Epub 2007 Feb 12.

Abstract

Francisella tularensis, the causative agent of tularemia, has been designated a CDC category A select agent because of its low infective dose (<10 CFU), its ready transmission by aerosol, and its ability to produce severe morbidity and high mortality. The identification and characterization of this organism's virulence determinants will facilitate the development of a safe and effective vaccine. We report that inactivation of the wbtA-encoded dehydratase of the O-antigen polysaccharide (O-PS) locus of the still-unlicensed live vaccine strain of F. tularensis (LVS) results in a mutant (the LVS wbtA mutant) with remarkably attenuated virulence. Western blot analysis and immune electron microscopy studies associate this loss of virulence with a complete lack of surface O-PS expression. A likely mechanism for attenuation is shown to be the transformation from serum resistance in the wild-type strain to serum sensitivity in the mutant. Despite this significant attenuation in virulence, the LVS wbtA mutant remains immunogenic and confers protective immunity on mice against challenge with an otherwise lethal dose of either F. tularensis LVS or a fully virulent clinical isolate of F. tularensis type B. Recognition and characterization of the pivotal role of O-PS in the virulence of this intracellular bacterial pathogen may have broad implications for the creation of a safe and efficacious vaccine.

摘要

土拉弗朗西斯菌是兔热病的病原体,因其低感染剂量(<10 CFU)、易于通过气溶胶传播以及能够导致严重发病和高死亡率,已被美国疾病控制与预防中心指定为A类选择生物制剂。鉴定和表征该生物体的毒力决定因素将有助于开发安全有效的疫苗。我们报告称,对仍未获批的土拉弗朗西斯菌活疫苗株(LVS)的O抗原多糖(O-PS)位点的wbtA编码脱水酶进行失活,会产生一种毒力显著减弱的突变体(LVS wbtA突变体)。蛋白质免疫印迹分析和免疫电子显微镜研究表明,这种毒力丧失与表面O-PS表达完全缺失有关。毒力减弱的一个可能机制是从野生型菌株的血清抗性转变为突变体的血清敏感性。尽管毒力有显著减弱,但LVS wbtA突变体仍具有免疫原性,并能使小鼠获得针对致死剂量的土拉弗朗西斯菌LVS或B型完全毒力临床分离株攻击的保护性免疫。认识和表征O-PS在这种细胞内细菌病原体毒力中的关键作用,可能对开发安全有效的疫苗具有广泛意义。

相似文献

引用本文的文献

7
Adaptive Immunity to and Considerations for Vaccine Development.适应性免疫与疫苗开发的考虑因素。
Front Cell Infect Microbiol. 2018 Apr 6;8:115. doi: 10.3389/fcimb.2018.00115. eCollection 2018.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验